PDL BioPharma, Inc. (PDLI) Tops Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts PDLI Hot Sheet
Price: $2.47 --0%
Financial Fact:
Income tax expense: 14.4M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Income tax expense: 14.4M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
PDL BioPharma, Inc. (NASDAQ: PDLI) reported Q2 EPS of $0.52, $0.06 better than the analyst estimate of $0.46. Revenue for the quarter came in at $162.8 million versus the consensus estimate of $134.07 million.
For earnings history and earnings-related data on PDL BioPharma, Inc. (PDLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Nebius Group (NBIS) PT Raised to $300 at Compass Point
- Aeroflex Holdings (ARX) Tops Q2 EPS by 15c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
